Pharmaceuticals, Biotechnology and Life Sciences
Alvogen is selling its Central and Eastern European business to Zentiva, for an undisclosed amount, to focus on developing other areas, with the transaction to be closed in first quarter of 2020.
Vistin Pharma posted net financial gain for the third quarter NOK 68.1 million (€6.68M), compared to a net loss of NOK 4.3 million in the same period last year, resulting with the net financial gain for the quarter primarily relates to an unrealised gain on oil derivatives of NOK 66.7 million.
BERLIN–(BUSINESS WIRE)–Regulatory News: NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by…
PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #BMS—Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) flat…
Vertex got a deal with NHS England, to enable eligible patients with cystic fibrosis in England the access to Orkambi…
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), has completed patient enrollment in its Phase 2 clinical trial of AR-1105 in…
PARIS–(BUSINESS WIRE)–Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced sales for the third quarter…
ICON has acquired Symphony Clinical Research, to boost its ability to offer customers hybrid trial solutions and site support services,…
Janssen has submitted a type II variation application to European Medicines agency, looking to get approved guselkumab, which could then…
The CoFI™ System is indicated for diagnostic assessment of the coronary microcirculation immediately following PCI (“stenting”), and to be a…